MPN Clinical Trials

2 recruiting

MPN Trials at a Glance

17 actively recruiting trials for mpn are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in New York, Palo Alto, and Boston. Lead sponsors running mpn studies include Memorial Sloan Kettering Cancer Center, Fudan University, and Center for International Blood and Marrow Transplant Research.

Browse mpn trials by phase

Treatments under study

About MPN Clinical Trials

Looking for clinical trials for MPN? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MPN trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MPN clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Myelofibrosis (MF)Polycythemia Vera (PV)Myeloproliferative Neoplasms (MPNs)
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting
Phase 2

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled16 locationsNCT05985161
Recruiting
Phase 1Phase 2

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

MDS/MPN
Michael Savona94 enrolled4 locationsNCT04061421
Recruiting

DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins

MPNSTNeurofibromas
M.D. Anderson Cancer Center60 enrolled1 locationNCT07298083
Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 1Phase 2

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

MyelofibrosisMyeloproliferative NeoplasmPolycythemia Vera+2 more
University of California, Irvine27 enrolled2 locationsNCT05123365
Recruiting
Phase 1Phase 2

SPEARHEAD-3 Pediatric Study

OsteosarcomaSynovial SarcomaMalignant Peripheral Nerve Sheath Tumor (MPNST)+1 more
USWM CT, LLC20 enrolled10 locationsNCT05642455
Recruiting
Phase 2

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Malignant Peripheral Nerve Sheath Tumors (MPNST)
Memorial Sloan Kettering Cancer Center25 enrolled7 locationsNCT04872543
Recruiting
Phase 2

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

AngiosarcomaLeiomyosarcomaDesmoplastic Small Round Cell Tumor+4 more
Fudan University45 enrolled1 locationNCT06849986
Recruiting

Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

MDSMDS/MPN
University of Leipzig60 enrolled11 locationsNCT05582902
Recruiting
Early Phase 1

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Myelodysplastic SyndromesMDS/MPN Crossover Syndromes
Benjamin Tomlinson20 enrolled1 locationNCT04187703
Recruiting
Phase 1

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

MyelofibrosisEssential ThrombocythemiaMPN
Marina Kremyanskaya10 enrolled1 locationNCT05025488
Recruiting
Phase 2

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

MDS (Myelodysplastic Syndrome)Acute Myeloid LeukaemiaMPN (Myeloproliferative Neoplasms)
Istituto Clinico Humanitas42 enrolled2 locationsNCT06892223
Recruiting
Phase 3

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

Myeloproliferative Neoplasms (MPN)
Siriraj Hospital240 enrolled1 locationNCT06740916
Recruiting
Phase 2

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis.

Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Jubilant Therapeutics, Inc.30 enrolled3 locationsACTRN12624000478516
Recruiting

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Acute LeukemiaMDSMDS/MPN+1 more
Peking University People's Hospital300 enrolled1 locationNCT06211166
Recruiting
Phase 2

Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

MDS/MPN
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT05817955